Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
-Enrollment ongoing in clinical trials of CTX001™ for patients with severe hemoglobinopathies- -Enrollment ongoing in clinical trial of CTX110™, targeting CD19+ malignancies- -Began treating...
-
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
-
-Enrollment ongoing in clinical trials of CTX001™ for patients with severe hemoglobinopathies- -Enrollment ongoing in clinical trial of CTX110™, targeting CD19+ malignancies- -Enrollment has...
-
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
-
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
-
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for...
-
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for...
-
-Two patients treated with CTX001 successfully engrafted and demonstrated an initial safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell...
-
-Provides update from ongoing Phase 1/2 clinical trials of CTX001® for patients with severe hemoglobinopathies- -Began treating patients in Phase 1/2 clinical trial of CTX110™, targeting...
-
- CRISPR Therapeutics to receive non-exclusive access to certain KSQ IP for its allogeneic CAR-T programs - - KSQ Therapeutics to receive non-exclusive access to certain CRISPR IP for its autologous...